CORT News and Press, Corcept Therapeutics Incorporated From 09/23/22

Corcept Therapeutics Incorporated ( NASDAQ: CORT ), the maker of Cushing’s syndrome medication Korlym, has extended its partnership with specialty pharmacy Optime Care, Inc., for U.S. distribution of the treatment. As part of the Sep. 16 amendment to the pharmaceuti...

Summary Return on equity (ROE) may help to reveal profitable firms, but does Wall Street reward the stock prices of these firms? Warren Buffett considers it a positive sign when a company is able to earn above-average returns on equity. Return on equity can be simply stated as...

Summary Today, we put the spotlight on Corcept Therapeutics for the first time in more than a year. The company's Korlym is delivering steady sales and earning growth, the company has a solid balance sheet, and Corcept Therapeutics is also advancing its pipeline. An investment...

Image source: The Motley Fool. Corcept Therapeutics (NASDAQ: CORT) Q2 2022 Earnings Call Aug 03, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Corcept Therapeutics (CORT) Q2 2022 Earnings Call Transcript

Corcept Therapeutics Incorporated (CORT) Q2 2022 Earnings Conference Call Aug 3, 2022 5:00 PM ET Company Participants Joseph Belanoff - Chief Executive Officer, President, and Director Atabak Mokari - Chief Financial Officer Bill Guyer - Chief Development Officer...

Corcept Therapeutics press release ( NASDAQ: CORT ): Q2 GAAP EPS of $0.24. Revenue of $103.4M (+12.9% Y/Y). For further details see: Corcept Therapeutics GAAP EPS of $0.24, revenue of $103.4M

Citing a more balanced risk-reward profile following the recent outperformance of company shares, Truist downgraded commercial-stage pharma Corcept Therapeutics ( NASDAQ: CORT ) to Hold from Buy on Monday. The analyst Gregory Fraser highlights Corcept ( CORT ) shares...

Jefferies is assuming Corcept Therapeutics ( NASDAQ: CORT ) with a buy rating citing the profitability of the company's Cushing Syndrome drug Korlym. The firm has a price target of $35 (~31% upside based on Tuesday's close). Shares are up 8% in Wednesday morning trad...

NEW YORK, July 25, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Enochian Biosciences, Inc. (NASDAQ: ENOB), Corcept Therapeutics, Inc. (NASDAQ: CORT), Cassava Sciences, Inc. (NASDAQ: S...

NEW YORK, July 20, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Enochian Biosciences, Inc. (NASDAQ: ENOB), Corcept Therapeutics, Inc. (NASDAQ: CORT), Rollins, Inc. (NYSE: ROL), and Wo...